CD4 and neoplasm: Moreover, co-administration of IL-7 with tumor-reactive CD4+ T cells in a mouse model promotes their expansion, persistence and antitumor activity, corroborating the potential use of IL-7 as an adjuvant for CD4+ T cell-based ACT [190].